Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common stock, par value $0.00001 per share
-
Shares outstanding
-
52.9M
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
51.7M
-
Shares change
-
+216K
-
Total reported value, excl. options
-
$324M
-
Value change
-
+$3.13M
-
Put/Call ratio
-
0.17
-
Number of buys
-
57
-
Number of sells
-
-54
-
Price
-
$6.26
Significant Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q2 2023
132 filings reported holding PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share as of Q2 2023.
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.7M shares
of 52.9M outstanding shares and own 97.59% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.56M shares), BlackRock Inc. (4.68M shares), JPMORGAN CHASE & CO (4.08M shares), Boxer Capital, LLC (3.16M shares), Avoro Capital Advisors LLC (3.06M shares), RTW INVESTMENTS, LP (3.03M shares), Euclidean Capital LLC (2.55M shares), Verition Fund Management LLC (2.36M shares), CITADEL ADVISORS LLC (2.13M shares), and VANGUARD GROUP INC (2.04M shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.